268 AXL activation mediates both intrinsic and acquired resistance to targeted therapies (e.g., EGFR-TKIs in NSCLC, HER2 inhibitors in breast cancer), chemotherapy (e.g., cisplatin, gemcitabine), and antiangiogenic agents (e.g., bevacizumab)
How can a different workflow change the outcome
These broader health advantages reflect our philosophy at TrimRx: that true weight loss is not just about shedding pounds, but about fostering a healthier, more vibrant life
Keller Dr
Why that selectivity exists at the receptor level isnt entirely settled it may reflect biased agonism, where the specific binding geometry favors the somatotroph signaling pathway over the corticotroph one, even though both cell populations express GHSR-1a
A Business Group on Health survey of 105 large employer members, fielded in February and March 2026, found that 67 percent currently cover GLP-1 medications for weight management